Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasalcrom duration of use should be focus in labeling, advisory cmte. suggests.

This article was originally published in The Tan Sheet

Executive Summary

NASALCROM DURATION OF USE LABELING INSTRUCTIONS OF PARTICULAR IMPORT for consumers who take the nasal solution for treatment of perennial allergy symptoms, Pulmonary-Allergy Drugs Advisory Committee member John Jenne, MD, stated at an Oct. 10 joint meeting of the Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees in Bethesda, Md. The one-day meeting was held to discuss McNeil's Rx-to-OTC switch application for cromolyn sodium nasal spray. The joint committee recommended approval of the drug for OTC treatment and prevention of allergic rhinitis.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel